Inclusion body myositis: therapeutic approaches

References

• PhillipsBAZilkoPJMastagliaFLPrevalence of sporadic inclusion body myositis in Western AustraliaMuscle Nerve200023697097210842277
   PubMed Web of Science ®Google Scholar
• WilsonFCYtterbergSRSt SauverJLReedAMEpidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, MinnesotaJ Rheumatol200835344544718203321
   PubMed Web of Science ®Google Scholar
• MastagliaFLSporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHCActa Myol2009282667120128139
   PubMedGoogle Scholar
• PengAKoffmanBMMalleyJDDalakasMCDisease progression in sporadic inclusion body myositis: observations in 78 patientsNeurology200055229629810908910
   PubMed Web of Science ®Google Scholar
• RoseMRMcDermottMPThorntonCAPalenskiCMartensWBGriggsRCA prospective natural history study of inclusion body myositis: implications for clinical trialsNeurology200157354855011502935
   PubMed Web of Science ®Google Scholar
• DarrowDHHoffmanHTBarnesGJWileyCAManagement of dysphagia in inclusion body myositisArch Otolaryngol Head Neck Surg199211833133171313247
   PubMedGoogle Scholar
• VermaABradleyWGAdesinaAMSoffermanRPendleburyWWInclusion body myositis with cricopharyngeus muscle involvement and severe dysphagiaMuscle Nerve19911454704731651449
   PubMed Web of Science ®Google Scholar
• CoxFMReijnierseMvan RijswijkCSWintzenARVerschuurenJJBadrisingUAMagnetic resonance imaging of skeletal muscles in sporadic inclusion body myositisRheumatology (Oxford)20115061153116121288962
   PubMed Web of Science ®Google Scholar
• BarohnRJAmatoAASahenkZKisselJTMendellJRInclusion body myositis: explanation for poor response to immunosuppressive therapyNeurology1995457130213047617187
   PubMed Web of Science ®Google Scholar
• TawilRGriggsRCInclusion body myositisCurr Opin Rheumatol200214665365712410086
   PubMed Web of Science ®Google Scholar
• CarpenterSKarpatiGSporadic diseases of skeletal muscle: inclusion body myositisCarpenterSKarpatiGPathology of Skeletal Muscle2nd edNew York, NYOxford University Press2001
   Google Scholar
• MendellJRSahenkZGalesTPaulLAmyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filamentsArch Neurol19914812122912341668977
   PubMedGoogle Scholar
• GriggsRCAskanasVDiMauroSInclusion body myositis and myopathiesAnn Neurol19953857057137486861
   PubMed Web of Science ®Google Scholar
• AmatoAAGronsethGSJacksonCEInclusion body myositis: clinical and pathological boundariesAnn Neurol19964045815868871577
   PubMed Web of Science ®Google Scholar
• van der MeulenMFHoogendijkJEJansenGHVeldmanHWokkeJHAbsence of characteristic features in two patients with inclusion body myositisJ Neurol Neurosurg Psychiatry19986433963989527159
   PubMed Web of Science ®Google Scholar
• CalabreseLHMitsumotoHChouSMInclusion body myositis presenting as treatment-resistant polymyositisArthritis Rheum19873043974033034295
   PubMed Web of Science ®Google Scholar
• GreenbergSAInclusion body myositis: review of recent literatureCurr Neurol Neurosci Rep200991838919080758
   PubMed Web of Science ®Google Scholar
• BenvenisteOHilton-JonesDInternational Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on May 29, 2009Neuromuscul Disord201020641442120413309
   PubMedGoogle Scholar
• Hilton-JonesDMillerAPartonMHoltonJSewryCHannaMGInclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, June 13, 2008Neuromuscul Disord201020214214720074951
   PubMed Web of Science ®Google Scholar
• HoogendijkJEAmatoAALeckyBR119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, October 10–12, 2003, Naarden, The NetherlandsNeuromuscul Disord200414533734515099594
   PubMedGoogle Scholar
• BadrisingUAMaat-SchiemanMvan DuinenSGEpidemiology of inclusion body myositis in the Netherlands: a nationwide studyNeurology20005591385138711087787
   PubMed Web of Science ®Google Scholar
• ChahinNEngelAGCorrelation of muscle biopsy, clinical course, and outcome in PM and sporadic IBMNeurology200870641842417881720
   PubMed Web of Science ®Google Scholar
• BenvenisteOGuiguetMFreebodyJLong-term observational study of sporadic inclusion body myositisBrain2011134Pt 113176318421994327
   PubMed Web of Science ®Google Scholar
• CoxFMTitulaerMJSontJKWintzenARVerschuurenJJBadrisingUAA 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilitiesBrain2011134Pt 113167317521908393
   PubMed Web of Science ®Google Scholar
• DalakasMCTherapeutic targets in patients with inflammatory myopathies: present approaches and a look to the futureNeuromuscul Disord200616422323616542836
   PubMed Web of Science ®Google Scholar
• GriggsRCThe current status of treatment for inclusion-body myositisNeurology2006662 Suppl 1S30S3216432142
   PubMed Web of Science ®Google Scholar
• LotzBPEngelAGNishinoHStevensJCLitchyWJInclusion body myositis. Observations in 40 patientsBrain1989112Pt 37277472543478
   PubMed Web of Science ®Google Scholar
• CohenMRSulaimanARGarancisJCWortmannRLClinical heterogeneity and treatment response in inclusion body myositisArthritis Rheum19893267347402544185
   PubMed Web of Science ®Google Scholar
• DerkCTVivinoFBKenyonLMandelSInclusion body myositis in connective tissue disorders: case report and review of the literatureClin Rheumatol2003224–532432814576992
   PubMed Web of Science ®Google Scholar
• JoffeMMLoveLALeffRLDrug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacyAm J Med19939443793878386437
   PubMed Web of Science ®Google Scholar
• SayersMEChouSMCalabreseLHInclusion body myositis:analysis of 32 casesJ Rheumatol1992199138513891331441
   PubMed Web of Science ®Google Scholar
• HopkinsonNDHuntCPowellRJLoweJInclusion body myositis: an underdiagnosed condition?Ann Rheum Dis19935221471518383483
   PubMed Web of Science ®Google Scholar
• LeffRLMillerFWHicksJFraserDDPlotzPHThe treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapyMedicine (Baltimore)19937242252358393509
   PubMed Web of Science ®Google Scholar
• BeyenburgSZierzSJerusalemFInclusion body myositis: clinical and histopathological features of 36 patientsClin Investig1993715351361
   PubMedGoogle Scholar
• YoodRASmithTWInclusion body myositis and systemic lupus erythematosusJ Rheumatol19851235685702995660
   PubMed Web of Science ®Google Scholar
• BadrisingUAMaat-SchiemanMLFerrariMDComparison of weakness progression in inclusion body myositis during treatment with methotrexate or placeboAnn Neurol200251336937211891832
   PubMed Web of Science ®Google Scholar
• MowzoonNSussmanABradleyWGMycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositisJ Neurol Sci2001185211912211311292
   PubMed Web of Science ®Google Scholar
• ArahataKEngelAGMonoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cellsAnn Neurol19841621932086383191
   PubMed Web of Science ®Google Scholar
• MuntzingKLindbergCMoslemiAROldforsAInclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over timeScand J Immunol200358219520012869141
   PubMed Web of Science ®Google Scholar
• QuartuccioLDe MarchiGScottCAFerraccioliGBeltramiCADe VitaSTreatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune featuresClin Exp Rheumatol200725224625117543149
   PubMed Web of Science ®Google Scholar
• LindbergCTrysbergETarkowskiAOldforsAAnti-T-lymphocyte globulin treatment in inclusion body myositis:a randomized pilot studyNeurology200361226026212874415
   PubMed Web of Science ®Google Scholar
• LindbergCPerssonLIBjorkanderJOldforsAInclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 casesActa Neurol Scand19948921231318191875
   PubMed Web of Science ®Google Scholar
• MoriSHamadaHYokoyamaASevere inclusion body myositis with interstitial pneumoniaIntern Med200140994094411579961
   PubMed Web of Science ®Google Scholar
• SoueidanSADalakasMCTreatment of inclusion-body myositis with high-dose intravenous immunoglobulinNeurology19934358768798492940
   PubMed Web of Science ®Google Scholar
• AmatoAABarohnRJJacksonCEPappertEJSahenkZKisselJTInclusion body myositis: treatment with intravenous immunoglobulinNeurology1994448151615188058161
   PubMed Web of Science ®Google Scholar
• WalterMCLochmullerHToepferMHigh-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled studyJ Neurol20002471222810701893
   PubMed Web of Science ®Google Scholar
• DalakasMCSoniesBDambrosiaJSekulECuplerESivakumarKTreatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled studyNeurology19974837127169065553
   PubMed Web of Science ®Google Scholar
• WolfHMEiblMMImmunomodulatory effect of immunoglobulinsClin Exp Rheumatol199614Suppl 15S17S25
   Google Scholar
• FujiiMSivakumarKDalakasMCHistologic characteristics in repeated muscle biopsies of patients with inclusion body myositis (IBM) treated in a control trial with high-dose intravenous immunoglobulin (IVIg) and prednisoneNeurology199748Suppl 2A332A333
   Google Scholar
• CherinPPelletierSTeixeiraAIntravenous immunoglobulin for dysphagia of inclusion body myositisNeurology200258232611805271
   PubMed Web of Science ®Google Scholar
• MarieIHachullaELevesqueHIntravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositisJ Rheumatol199926122706270910606390
   PubMed Web of Science ®Google Scholar
• OhTHBrumfieldKAHoskinTLStolpKAMurrayJABassfordJRDysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patientsMayo Clinic Proc2007824441447
   PubMed Web of Science ®Google Scholar
• OhTHBrumfieldKAHoskinTLKasperbauerJLBasfordJRDysphagia in inclusion body myositis: clinical features, management, and clinical outcomeAm J Phys Med Rehabil2008871188388918936555
   PubMed Web of Science ®Google Scholar
• HouserSMCalabreseLHStromeMDysphagia in patients with inclusion body myositisLaryngoscope19981087100110059665246
   PubMed Web of Science ®Google Scholar
• LiuLWTarnopolskyMArmstrongDInjection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositisCan J Gastroenterol200418639739915190396
   PubMed Web of Science ®Google Scholar
• Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositisNeurology20015791566157011706093
   PubMed Web of Science ®Google Scholar
• Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositisNeurology200463471872015326251
   PubMed Web of Science ®Google Scholar
• WarabiYMatsubaraSMizutaniTHayashiHInclusion body myositis after interferon-alpha treatment in a patient with HCV and HTLV-1 infectionRinsho Shinkeigaku200444960961415515704
   PubMedGoogle Scholar
• YakushijiYSatohJYukitakeMInterferon beta-responsive inclusion body myositis in a hepatitis C virus carrierNeurology200463358758815304605
   PubMed Web of Science ®Google Scholar
• HaleGWaldermannHFrom Laboratory to Clinic: the story of CAMPATH-1Clifton, NJHumana Press2000
   Google Scholar
• ColesAJCompstonDASelmajKWAlemtuzumab vs interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• DalakasMCRakocevicGSchmidtJEffect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositisBrain2009132Pt 61536154419454532
   PubMed Web of Science ®Google Scholar
• LepidiHFrancesVFigarella-BrangerDBartoliCMachado-BaetaAPellissierJFLocal expression of cytokines in idiopathic inflammatory myopathiesNeuropathol Appl Neurobiol199824173799549732
   PubMed Web of Science ®Google Scholar
• De BleeckerJLMeireVIDeclercqWVan AkenEHImmunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathiesNeuromuscul Disord19999423924610399751
   PubMed Web of Science ®Google Scholar
• BarohnRJHerbelinLKisselJTPilot trial of etanercept in the treatment of inclusion-body myositisNeurology2006662 Suppl 1S123S12416432140
   PubMed Web of Science ®Google Scholar
• DastmalchiMGrundtmanCAlexandersonHA high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathiesAnn Rheum Dis200867121670167718272672
   PubMed Web of Science ®Google Scholar
• Ramos-CasalsMBrito-ZeronPMunozSAutoimmune diseases induced by TNF-targeted therapies: analysis of 233 casesMedicine (Baltimore)200786424225117632266
   PubMed Web of Science ®Google Scholar
• KallaRSoumakiyanMTuckSA case of inclusion body myositis responsive to prednisolone therapyClin Rheum200928Suppl 1S21S22
   Web of Science ®Google Scholar
• VordenbaumenSNeuen-JacobERichterJSchneiderMInclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFalpha and rituximabClin Rheum2010295555558
   Web of Science ®Google Scholar
• BradshawEMOrihuelaAMcArdelSLA local antigen-driven humoral response is present in the inflammatory myopathiesJ Immunol2007178154755617182595
   PubMed Web of Science ®Google Scholar
• SultanSMNgKPEdwardsJCIsenbergDACambridgeGClinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathyClin Exp Rheumatol200826588789319032824
   PubMed Web of Science ®Google Scholar
• BhasinSStorerTWBermanNThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal menN Engl J Med19963351178637535
   PubMed Web of Science ®Google Scholar
• FenichelGPestronkAFlorenceJRobisonVHemeltVA beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot studyNeurology1997485122512269153447
   PubMed Web of Science ®Google Scholar
• FenichelGMGriggsRCKisselJA randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophyNeurology20015681075107911320181
   PubMed Web of Science ®Google Scholar
• RutkoveSBParkerRANardinRAConnollyCEFeliceKJRaynorEMA pilot randomized trial of oxandrolone in inclusion body myositisNeurology20025871081108711940697
   PubMed Web of Science ®Google Scholar
• ChungYLAlexandersonHPipitoneNCreatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trialArthritis Rheum200757469470217471547
   PubMed Web of Science ®Google Scholar
• WiesingerGFQuittanMGraningerMBenefit of 6 months long-term physical training in polymyositis/dermatomyositis patientsBr J Rheumatol19983712133813429973161
   PubMedGoogle Scholar
• WiesingerGFQuittanMAringerMImprovement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programmeBr J Rheumatol19983721962009569076
   PubMedGoogle Scholar
• AlexandersonHStenstromCHLundbergISafety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot studyRheumatology (Oxford)199938760861110461472
   PubMed Web of Science ®Google Scholar
• ArnardottirSAlexandersonHLundbergIEBorgKSporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reactionJ Rehabil Med2003351313512610846
   PubMed Web of Science ®Google Scholar
• SpectorSALemmerJTKoffmanBMSafety and efficacy of strength training in patients with sporadic inclusion body myositisMuscle Nerve19972010124212489324080
   PubMed Web of Science ®Google Scholar
• JohnsonLGCollierKEEdwardsDJImprovement in aerobic capacity after an exercise program in sporadic inclusion body myositisJ Clin Neuromuscul Dis200910417818419494728
   PubMedGoogle Scholar
• LloydTENovel therapeutic approaches for inclusion body myositisCurr Opin Rheumatol201022665866420827206
   PubMed Web of Science ®Google Scholar